Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 4
in 77 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arrowhead Pharmaceuticals’ revenue fell year over year in the fourth fiscal quarter of 2026, based on preliminary results reported November 12, 2026, with revenue down 85.3% to about $37.8 million from roughly $256.5 million a year ago. Gross profit came in at about $29.0 million, putting gross margin at ~77%, as the company continued to generate revenue while investing across its RNA interference therapeutics pipeline. Consensus for the next period calls for EPS of -$1.45 on revenue of $45.0 million.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biotechnology company that develops RNA interference medicines for complex diseases, with activity centered in the United States. In FY2025, the company recorded $829.4 million in revenue as it advanced a pipeline spanning liver, cardiometabolic, pulmonary, oncology, neuromuscular, inflammatory, and infectious-disease programs.
Today's Snapshot
The day ended with ARWR slightly higher at 43.11, while its sector was weaker. Arrowhead Pharmaceuticals said new prescriptions for its FCS drug REDEMPLO rose 63% sequentially in its U.S. launch.
Trading Volume
Below 10d avg (2.9M)
2.1M
vs S&P 500 Today
Outperforming Market
+0.54%
Updated: November 18, 2026 at 21:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$48.27 - $66.76Sell
- RSI (14)21.29Buy
- Stochastic %K (14, 3, 3)3.54Buy
- MACD Level (12, 26)-5.04Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.